Key result
E-4031 significantly increased the overall right atrial effective refractory period from 210 ms to 232 ms (p < 0.001) and decreased the incidence of repetitive atrial firing.
Why the study?
Does the class III antiarrhythmic agent E-4031 alter electrophysiological properties such as refractoriness and conduction in human atrial muscle in vivo?
Population
10 patients, mean age 54 (SD 11) years undergoing in vivo electrophysiological measurements
Comparison
E-4031 vs Baseline (measurements taken before infusion)
Design
Other
Authors
Loading...
May support E-4031 testing in paroxysmal AF; hypothesis-generating and requires randomized confirmation.
Does the class III antiarrhythmic agent E-4031 alter electrophysiological properties such as refractoriness and conduction in human atrial muscle in vivo?
Absolute Event Rate: 232% vs 210%
p-value: p=< 0.001
E-4031 prolongs the atrial effective refractory period and reduces repetitive atrial firing, suggesting potential efficacy for treating paroxysmal atrial fibrillation.
Shimizu et al. (1993) studied Paroxysmal atrial fibrillation (n=10). E-4031 vs. Baseline (before infusion) was evaluated on Overall right atrial effective refractory period (p=< 0.001). E-4031 significantly increased the overall right atrial effective refractory period from 210 ms to 232 ms (p < 0.001) and decreased the incidence of repetitive atrial firing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: